Free Trial
Steve Seedhouse

Steve Seedhouse Analyst Performance

Equity Research- Biotechnology at Cantor Fitzgerald

Steve Seedhouse is a stock analyst at Cantor Fitzgerald in the medical sector, covering 6 publicly traded companies. Over the past year, Steve Seedhouse has issued 8 stock ratings, including strong buy and buy recommendations. While full access to Steve Seedhouse's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Steve Seedhouse's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 0 Years
Buy Recommendations
100.00% 8 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy25.0%2 ratings
Buy75.0%6 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 8 total stock ratings issued by Steve Seedhouse at Cantor Fitzgerald, the majority (75.0%) have been Buy recommendations, followed by 25.0% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Steve Seedhouse, an analyst at Cantor Fitzgerald, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Steve Seedhouse of Cantor Fitzgerald specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
50.0%
MED - DRUGS
2 companies
33.3%
LARGE CAP PHARMA
1 company
16.7%

Steve Seedhouse's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Xencor, Inc. stock logo
XNCR
Xencor
10/8/2025Upgrade$12.40Strong-Buy
Xencor, Inc. stock logo
XNCR
Xencor
10/6/2025Reiterated Rating$12.07$40.00Overweight
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
10/2/2025Set Price Target$2.98$7.00Overweight
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
10/2/2025Upgrade$3.00$7.00Strong-Buy
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
8/1/2025Boost Price Target$23.27$40.00Overweight
Innoviva, Inc. stock logo
INVA
Innoviva
7/11/2025Initiated Coverage$19.06$26.00Overweight
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
7/11/2025Initiated Coverage$22.67$52.00Overweight
Harrow, Inc. stock logo
HROW
Harrow
7/11/2025Initiated Coverage$31.37$76.00Overweight